Danaher Beats Q1 Expectations, Signals Caution Ahead In 'Unusual Times'

1. DHR reported Q1 2025 sales of $5.74 billion, up from consensus. 2. Non-GAAP core revenue was flat, beating low expectations of decline. 3. Adjusted EPS for Q2 reached $1.88, exceeding consensus forecast. 4. Bioprocessing sales grew notably, impacting overall revenue positively. 5. DHR reaffirms FY2025 guidance for low single-digit revenue growth.